A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study

By afschroeder • September 15, 2026

Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel J, Coleman CI, Aguiar C, Ripoll-Vera T. A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study. J Comp Eff Res. 2026 Sep 14:e260114. doi: 10.57264/cer-2026-0114. Epub ahead of print. PMID: 42734113.

Tags: acoramidis, all-cause mortality, ATTR-CM, comparative effectiveness research, General Internal Medicine, Publications, tafamidis, Target trial emulation, transthyretin amyloid cardiomyopathy, transthyretin stabilizer

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Primary care physician characteristics and potentially inappropriate medications in older adults

Tatsuno Y, Sarkisian CA, Mafi JN, Kitajima K, Sato D, Tsugawa Y, Miyawaki A. Primary care physician characteristics and potentially inappropriate medications in older adults.[...]

When Prior Exposure Doesn’t Protect: Imported Plasmodium falciparum Malaria in a Returning Traveler With Waning Immunity

Nguyen M, Khan N, Patel N, Greeley A, Moriates C. When Prior Exposure Doesn't Protect: Imported Plasmodium falciparum Malaria in a Returning Traveler With Waning[...]